Literature DB >> 19746287

[Adipogenesis and osteoporosis].

Juan Pablo Rodríguez1, Pablo Astudillo, Susana Ríos, Germán Seitz, Ana María Pino.   

Abstract

Mesenchymal stem cells (MSCs) found in bone marrow stroma, are able to differentiate into osteoblasts and adipocytes, among other cellphenotypes. In normal bone marrow balance osteoblastic an adipocytes cell differentiation favour bone formation, while in osteoporosis there is an increased adipocytes content. Since osteoblasts and adipocytes originate from a common MSC precursor cell, here we discuss whether quantitative and qualitative stem cell defects may be the cause of alterations in the number and function of differentiated cells. This review analyzes some conditions that contribute to different osteogenic/adipogenic potentials in human bone marrow MSCs obtained from control and osteoporotic postmenopausal women. We analyze the protective effect exerted by locally generated factors like estradiol and leptin on MSCs differentiation, because altered bioavailability of these factors may play a role in osteoporosis. Osteoporotic MSCs (o-MSCs) are characterized by increased adipogenic potential as compared to control cells. Leptin exerted a direct protective action against adiposeness only in control cells. In contrast, leptin action on o-MSCs is hampered, suggesting that inadequate leptin action may be associated to lipid accumulation in bone marrow.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19746287     DOI: /S0034-98872009000600015

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  2 in total

1.  Treadmill training prevents bone loss by inhibition of PPARγ expression but not promoting of Runx2 expression in ovariectomized rats.

Authors:  Yongjie Chen; Shouhui Wang; Shumin Bu; Yingjie Wang; Yushuang Duan; Shaofeng Yang
Journal:  Eur J Appl Physiol       Date:  2011-01-09       Impact factor: 3.078

2.  Emodin enhances osteogenesis and inhibits adipogenesis.

Authors:  Feng Yang; Pu-wei Yuan; Yang-Quan Hao; Zheng-Mao Lu
Journal:  BMC Complement Altern Med       Date:  2014-02-24       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.